T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new study. Researchers at Karolinska Institutet have investigated how immune cells ...

T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...

For patients with hepatitis B virus, alcohol is associated with dose-dependent increased risks for cirrhosis and he ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in ...

Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.

A new study shows that long-read sequencing has the potential to improve the rate of diagnosis while reducing the time to diagnosis from years to days -- in a single test and at a much lower cost.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The American Gastroenterology Association (AGA) issued a new clinical guideline recommending antiviral drugs for patients at ...

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”) ...

Coherus markets LOQTORZI® (toripalimab-tpzi), a novel next-generation PD-1 inhibitor, and UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta. In December 2024, Coherus announced the planned ...

Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates ...